Drugs / IBI318
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04635527 | Dec 2020 → Aug 2021 | hepatocellular carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT04672928 | Dec 2020 → Jan 2023 | small cell lung carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03875157 | Apr 2019 → Feb 2023 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04611321 | Dec 2020 → Mar 2023 | skin squamous cell carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded |
| Phase 1/2 | NCT04602065 | Nov 2020 → Feb 2023 | extranodal nasal NK/T cell lymphoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04777084 | Aug 2021 → Dec 2024 overdue | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI318 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04611321 ↗ |
| Action | Inhibit | “anti-PD1/PD-L1” NCT04602065 ↗ |
| Route | Intravenous | “0.3 mg intravenous infusion” NCT03875157 ↗ |